JPM: Almirall maps out a busy 2026 for dermatology R&D
Spanish dermatology specialist Almirall (BME: ALM) is using its appearance at the 44th JP Morgan Healthcare Conference in San Francisco to set out an active 2026 clinical agenda, leaning into proof-of-concept work across immune-driven skin diseases and pushing one bispecific antibody into first-in-human testing.
Chief executive Carlos Gallardo is steering the firm’s R&D engine toward multiple shots on goal in parallel, with a focus on new treatments for conditions with stubborn unmet need. The firm frames the plan as a step-change in pace for a company that has historically been more selective.
Almirall said it currently has three proof-of-concept/Phase II studies underway: an anti-interleukin (IL)-1RAP monoclonal antibody for hidradenitis suppurativa, an IL-2muFc mutant fusion protein for alopecia areata, and an atopic dermatitis program led by Chinese partner Simcere.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
| Headless Content Management with Blaze